Condition (MeSH)
Hypertension, Renovascular
ClinicalTrials.gov lists 18 trials for Hypertension, Renovascular or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Hypertension, Renovascular itself; the rest are tagged with a narrower condition beneath it.
When did Hypertension, Renovascular trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 2 |
| 2019 | 1 |
| 2017 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 2 |
| 2009 | 1 |
| 2008 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypertension, Renovascular trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 6 |
| Observational | 5 |
How many Hypertension, Renovascular trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 8 |
| Terminated | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypertension, Renovascular trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Atrium Medical Corporation | 1 |
| Cook Group Incorporated | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| National Institutes of Health Clinical Center (CC) | 1 |
| Stealth BioTherapeutics Inc. | 1 |
Which drugs are being tested for Hypertension, Renovascular? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Elamipretide | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Arterial infusion of autologous mesenchymal stem cells | 1 |
| MRI | 1 |
| Optimal Medical Therapy | 1 |
| Medical Treatment | 1 |
| Atacand/HCT, Caduet | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypertension, Renovascular trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac Disorders | 245 | 1 |
| Infections and Infestations | 132 | 1 |
| Nervous System Disorders | 128 | 1 |
| Gastrointestinal Disorders | 99 | 1 |
| General Disorders | 74 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hypertension, Renovascular? (46)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Insights from intravascular pressure measurement of renal artery revascularization in patients with fibromuscular dysplasia: The DYSART study. | Journal of vascular surgery | 2022 | Yes |
| Atherosclerotic Renal Artery Stenosis. | Advances in experimental medicine and biology | 2017 | Yes |
| A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR) - one-year results of a pre-maturely terminated study. | Trials | 2017 | Yes |
| Early atherosclerosis aggravates renal microvascular loss and fibrosis in swine renal artery stenosis. | Journal of the American Society of Hypertension : JASH | 2016 | Yes |
| Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. | The American journal of the medical sciences | 2016 | Yes |
Showing 5 of 46 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.